Analysis of the value of new drug approvals over the past two decades, together with spending by industry on research and development (R&D), indicates that the R&D productivity for the industry overall has moved back towards a sustainable level, driven by several companies that are substantially outperforming the average.
- Ulrik Schulze
- Mathias Baedeker
- David Greber